Genematrix KRX:109820KOSDAQ
진매트릭스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days2
DART filings, 7 days0
Articles tracked2since Sep 11
In Q2 2026, Genematrix reported revenue of ₩2.9bn, up 8.1% year on year, and operating profit of ₩393m. Genematrix (진매트릭스) appeared in 2 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 14 with 2 articles. The most common catalyst was clinical & approvals (2).
Genematrix quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩2.9bn | +8.1% | ₩393m | ₩689m |
| Q1 2026 | ₩2.5bn | +0.9% | −₩327m | −₩221m |
| Q4 2025 derived | ₩2.9bn | +9.2% | −₩191m | −₩923m |
| Q3 2025 | ₩2.6bn | -1.7% | −₩109m | ₩266m |
| Q2 2025 | ₩2.7bn | -8.9% | −₩91m | −₩391m |
| Q1 2025 | ₩2.5bn | +38.2% | −₩288m | −₩786m |
| Q4 2024 derived | ₩2.6bn | -8.1% | −₩435m | −₩350m |
| Q3 2024 | ₩2.6bn | +7.1% | −₩148m | −₩193m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Genematrix top stories 2 weeks, by number of outlets
- 1
- 2
